Millennium & Copthorne Hotels New Zealand LimitedMCK

McKesson’s strongest sourced fact is scale with filing trail attached: SEC EDGAR filed revenue from contracts with customers of $403.43B in the 10-K period ending 2026-03-31. The current public-development rail is filing-led, with a 2026-07-08 Form 4, a 2026-07-07 Form 144, a 2026-07-01 8-K and a 2026-06-30 DEFA14A all listed from SEC EDGAR.

The company story underneath the ticker is healthcare distribution and pharmacy infrastructure. Official McKesson product pages describe distribution services for medical supplies and pharmaceuticals across the U.S., more than 300,000 national brand products plus McKesson’s own line through U.S. distribution centres, consumer health products, pharmacy care solutions and 3PL services for biopharma companies distributing therapies.

The latest supplied financial rail is the 10-K for the period ending 2026-03-31. It shows net income attributable to parent of $4.76B, operating income of $6.21B, assets of $82.32B, cash and cash equivalents of $3.98B, net cash provided by operating activities of $6.16B, capital expenditure on property, plant and equipment of $436.0M, inventory of $24.21B, diluted EPS of $38.38 and diluted weighted average shares of 124.1M.

The source-change rail is filing/source-led and does not use chart-derived signals. Chart context is available separately on this page through the Atlas chart snapshot or TradingView route where available. The market mechanism that can be described from the rail is operating rather than technical: a large healthcare distributor converts product access, customer demand, inventory control and payment flows into the filed revenue, profit and cash-flow lines.

The risk side is not vague. The 10-K says sales to the ten largest customers, including GPOs, accounted for about 73% of fiscal 2026 consolidated revenues, while sales to the next two largest customers accounted for 11% and 10%. It also says the One Big Beautiful Bill, enacted in July 2025, includes provisions expected to reduce Medicaid enrolment and federal funding to state Medicaid programmes, which may limit coverage or payment for products and services and affect customer stability.

What remains unproven in this source pack is equally important. The official product pages prove the breadth of distribution, consumer health, pharmacy and biopharma logistics services, but they do not prove a fresh product launch beyond the supplied consumer-health page reference to McKesson unveiling a new private brand of over-the-counter pharmacy products. The filings prove current disclosure activity, but the rail does not provide a newer earnings release, guidance update or price chart.